A Study of VET3-TGI in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT06444815. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Study identification
- NCT ID
- NCT06444815
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- KaliVir Immunotherapeutics
- Industry
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Cervical Cancer
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Head and Neck Squamous Cell Carcinoma
- Kidney Cancer
- Melanoma Stage IV
- Merkel Cell Carcinoma of Skin
- Mesothelioma
- Microsatellite Stable Colorectal Cancer
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Solid Tumor, Adult
- Squamous Cell Carcinoma
- Urothelial Carcinoma Bladder
Interventions
- Atezolizumab Drug
- VET3-TGI Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 15, 2024
- Primary completion
- Sep 29, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Apr 6, 2026
2024 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| UC Irvine Health | Orange | California | 92868 | Recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| Community Health Network | Indianapolis | Indiana | 46250 | Recruiting |
| UPMC- Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06444815, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06444815 live on ClinicalTrials.gov.